Relevant bibliographies by topics / Premixed Insulin NovoMix

Contents

  1. Journal articles

Academic literature on the topic 'Premixed Insulin NovoMix'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Premixed Insulin NovoMix.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Premixed Insulin NovoMix"

1

Gerő, László, András Gyimesi, Tibor Hidvégi, and István Jánosi. "Improvement in glycemic control, cardiovascular risk factors and anthropometric data in type 2 diabetic patients after the switch from biphasic human insulin to biphasic premix analog insulin aspart." Orvosi Hetilap 150, no. 35 (2009): 1637–47. http://dx.doi.org/10.1556/oh.2009.28705.

Full text
Abstract:
A nagyszámú 2-es típusú diabeteses beteg bevonásával végzett, hosszú távú vizsgálatok eredményei egyértelműen bizonyították, hogy a tartósan jó anyagcserehelyzettel megelőzhetők a késői (micro- és macrovascularis) szövődmények. Jelen felmérésben a szerzők beavatkozással nem járó, úgynevezett obszervációs vizsgálat során Magyarország 50 cukorbeteg-szakellátó helyén 2007–2008-ban humán premix készítményről analóg premix inzulinra [bifázisos aszpart inzulin (BIAsp) – NovoMix® 30] átállított betegek adatait elemzik retrospektív módon. Az analízisbe bevont 2898 beteg átlagéletkora 66,20 ± 10,10 év,
APA, Harvard, Vancouver, ISO, and other styles
2

Mohan, Viswanathan, Wolfgang Schmider, Kiran P. Singh, Baerbel Rotthaeuser, Bhaswati Mukherjee, and S. R. Aravind. "Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes." Indian Journal of Endocrinology and Metabolism 26, no. 4 (2022): 354–61. http://dx.doi.org/10.4103/ijem.ijem_216_22.

Full text
Abstract:
Background: We compared the pharmacokinetic exposure, efficacy, safety and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SARAsp-Mix) with its originator NovoMix® 30 insulin aspart mix (NN-Mix) in adults with type 2 diabetes. Methods: This was a randomized, open-label, parallel-group, substudy of the phase 3 GEMELLI M trial performed in three Indian centres. Totally 13 Indian participants previously treated with premix insulin received a single subcutaneous 0.3 U/kg dose of each treatment and underwent pharmacokinetic sampling for 16 h after dosing. Participants were t
APA, Harvard, Vancouver, ISO, and other styles
3

Shah, S., M. Benroubi, V. Borzi, et al. "Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix®30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study." International Journal of Clinical Practice 63, no. 4 (2009): 574–82. http://dx.doi.org/10.1111/j.1742-1241.2009.02012.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Aziz, KMA. "Application of Premixed Insulin NovoMix®30 and NovoRapid® as Multiple Daily Injections or as Basal Bolus Format in Selected Diabetic Patients: Practical Evidence from Prospective Case Series." May 8, 2017. https://doi.org/10.19070/2328-353X-1700013e.

Full text
Abstract:
Managing type-1 or type-2 diabetes by insulin is one of the best techniques, especially for type-2 diabetics after oral hypoglycemic agents (OHAs) failure. Multiple daily injections (MDI) or basal bolus methodology is an ideal regimen for type-1 diabetics [1, 2]. However, it is a difficult option for type-2 diabetic patients, especially older age groups. Most of type-2 diabetics usually prefer two injections per day, in the morning and evening. Analog premixed biphasic insulins include NovoMix® 30, Humalog Mix® 25 and Humalog Mix® 50. These insulin analogs are also recommended because of their
APA, Harvard, Vancouver, ISO, and other styles
5

Krajnc, Mitja, and Nika Aleksandra Kravos Tramšek. "Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?" European Journal of Medical Research 28, no. 1 (2023). http://dx.doi.org/10.1186/s40001-023-01081-y.

Full text
Abstract:
Abstract Background There are insufficient data on continuous glucose monitoring (CGM) in nonintensive insulin therapy patients. Using CGM and the recommended CGM targets, we wanted to evaluate low-premix insulin analogue therapy (biphasic aspart/NovoMix 30 and biphasic lispro 25/Humalog Mix 25) in real-world type 2 diabetes patients for glycaemic efficacy and especially hypoglycaemia. Methods The prospective observational study was performed on 35 patients who were treated with a low-premixed insulin. We used the Dexcom G6 system for CGM (9.6 ± 1 days) to measure the clinically relevant CGM p
APA, Harvard, Vancouver, ISO, and other styles
6

KMA, Aziz. "Application of Premixed Insulin NovoMix®30 and NovoRapid® as Multiple Daily Injections or as Basal Bolus Format in Selected Diabetic Patients: Practical Evidence from Prospective Case Series." International Journal of Diabetology & Vascular Disease Research, May 8, 2017, 1–2. http://dx.doi.org/10.19070/2328-353x-1700013e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Walt, Joshua R., Julie Loughran, Spiros Fourlanos, et al. "Glycaemic outcomes in hospital with IDegAsp versus BIAsp30 premixed insulins." Internal Medicine Journal, April 5, 2024. http://dx.doi.org/10.1111/imj.16391.

Full text
Abstract:
AbstractBackground and AimsIDegAsp (Ryzodeg 70/30), a unique premixed formulation of long‐acting insulin degludec and rapid‐acting insulin aspart, is increasing in use. Management of IDegAsp during hospitalisation is challenging because of degludec's ultra‐long duration of action. We investigated inpatient glycaemia in patients treated with IDegAsp compared to biphasic insulin aspart (BIAsp30; Novomix30).MethodsWe performed a retrospective observational study at two hospitals assessing inpatients with type 2 diabetes treated with IDegAsp or BIAsp30 prior to and during hospital admission. Stand
APA, Harvard, Vancouver, ISO, and other styles
8

Aravind, S. R., Kiran P. Singh, Grace Aquitania, et al. "Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)." Diabetes Therapy, April 14, 2022. http://dx.doi.org/10.1007/s13300-022-01255-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography